Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline, Pulsus Group Inc
CANADIAN RESPIRATORY JOURNAL
The Canadian Thoracic Society (CTS) Canadian Respiratory Health Professionals Canadian Critical Care Society (CCCS)

Note: (Optional)

Citation Builder

  •  
Return to Guidelines
 
Special Articles March/April 2012, Volume 19 Issue 2: 109-116
 

Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline

DD Marciniuk | P Hernandez | M Balter | J Bourbeau | K Chapman | G Ford | J Lauzon | F Maltais | D O'Donnell | D Goodridge | C Strange | A Cave | K Curren | S Muthuri

Alpha-1 antitrypsin (A1AT) functions primarily to inhibit neutrophil elastase, and deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). Severe A1AT deficiency occurs in one in 5000 to one in 5500 of the North American population. While the exact prevalence of A1AT deficiency in patients with diagnosed COPD is not known, results from small studies provide estimates of 1% to 5%. The present document updates a previous Canadian Thoracic Society position statement from 2001, and was initiated because of lack of consensus and understanding of appropriate patients suitable for targeted testing for A1AT deficiency, and for the use of A1AT augmentation therapy. Using revised guideline development methodology, the present clinical practice guideline document systematically reviews the published literature and provides an evidence-based update. The evidence supports the practice that targeted testing for A1AT deficiency be considered in individuals with COPD diagnosed before 65 years of age or with a smoking history of <20 pack years. The evidence also supports consideration of A1AT augmentation therapy in nonsmoking or exsmoking patients with COPD (forced expiratory volume in 1 s of 25% to 80% predicted) attributable to emphysema and documented A1AT deficiency (level ≤11 µmol/L) who are receiving optimal pharmacological and nonpharmacological therapies (including comprehensive case management and pulmonary rehabilitation) because of benefits in computed tomography scan lung density and mortality.

 
Corrigenda/Errata/Addenda
Published in:2012 ; volume 19: issue:4 page: 272

In the March/April issue of the Journal (Can Respir J 2012;19[2]:109-16), the name of the first author of reference 1 was omitted. The correct reference should have read:

1. Abboud RT, Ford GT, Chapman KR, on behalf of the Standards Committee of the Canadian Thoracic Society. Alpha1-antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J 2001;8:81-8.


Alpha-1 antitrypsin | Augmentation therapy | Deficiency | COPD | Emphysema
   Français   
          
Click to download PDF Reader
 
 




Copyright © Pulsus Group Inc.